Episodes

  • AOTI’s Dr Mike Griffiths on breakthrough for diabetic foot ulcers, chronic wound care

    AOTI’s Dr Mike Griffiths on breakthrough for diabetic foot ulcers, chronic wound care
    Jan 27 2025
    AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing. Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and ability to reduce hospitalisations and amputations resonate strongly with payers and healthcare providers. He also shared recent milestones, including the company’s expansion into six Medicaid states, its five-year renewal of the Veterans Affairs contract, and ongoing efforts to broaden its international presence. Griffiths announced the start of enrolments for the venous leg ulcer (VLU) clinical trial and discussed its significance in building high-quality evidence for AOTI's therapy. AOTI, headquartered in the US and listed on AIM, has grown by over 30% annually for five years and Griffiths expects this growth to continue as it enters new markets like skilled nursing and long-term care. “We believe we’re in a very exciting sector, with solutions that deliver long-term outcomes,” he shared. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for updates! #AOTI #ChronicWoundCare #DiabeticFootUlcers #MedicalTechnology #HealthcareInnovation #OxygenTherapy #Medicaid #VeteransAffairs #ClinicalTrials #MedTechGrowth
    Show more Show less
    7 mins
  • Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology

    Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology
    Jan 27 2025
    Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties. Sona’s proprietary technology employs patented, biocompatible gold nanorods (GNRs) to deliver precision, non-invasive hyperthermia therapy directly to cancer cells. This approach minimizes systemic toxicity, a common drawback of traditional cancer treatments. The study demonstrated that Sona’s THT induces cancer-specific cell death while triggering a robust immune response, marking a significant breakthrough in cancer immunotherapy. Notably, the research revealed that the immune response activated by Sona’s THT is effective against cancers that are typically resistant to modern immunotherapies. This novel immunity offers a critical advantage, paving the way for new treatment possibilities in cases where conventional methods fall short. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #GoldNanorods #TargetedTherapy #Biotechnology #CancerTreatment #HyperthermiaTherapy #Immunology #MedicalBreakthroughs #Nanotechnology
    Show more Show less
    6 mins
  • Fineqia International CEO unveils first DeFi yield ETP

    Fineqia International CEO unveils first DeFi yield ETP
    Jan 27 2025
    Fineqia International Inc CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell
    Show more Show less
    8 mins
  • hVIVO partners with ILiAD Biotechnologies for pivotal Phase 3 human challenge trial

    hVIVO partners with ILiAD Biotechnologies for pivotal Phase 3 human challenge trial
    Jan 27 2025
    hVIVO PLC CEO Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's involvement in a world-first Phase 3 human challenge trial for a pertussis (whooping cough) vaccine candidate. The trial, in partnership with ILiAD Biotechnologies, is expected to start in the second half of this year. Khan highlighted the importance of this milestone for hVIVO, noting that it will be the company's largest challenge trial to date and its first bacterial challenge trial. The trial data aims to secure FDA marketing authorisation, marking a pivotal moment for the utility of human challenge trials in vaccine development. According to Khan, "The goal is to get a better vaccine to patients faster. Pertussis is a severe disease, particularly for infants, and there's an urgent need for new vaccines." He further explained that hVIVO's state-of-the-art Canary Wharf facility will play a critical role in supporting this trial, equipped with expanded laboratory capabilities for bacterial analysis. The trial comes as cases of pertussis are on the rise, increasing sixfold between 2023 and 2024. ILiAD Biotechnologies has also secured FDA fast-track status and an MHRA innovation passport for this vaccine candidate. Khan emphasised the partnership's goal of addressing this unmet medical need and delivering an effective vaccine to patients worldwide. Visit Proactive's YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for future updates. #hVIVO #VaccineDevelopment #WhoopingCough #Pertussis #ClinicalTrials #FDAApproval #BiotechInnovation #Phase3Trial #HumanChallengeTrials #HealthcareResearch
    Show more Show less
    6 mins
  • GoviEx Uranium unveils low-risk, high-reward Muntanga feasibility study

    GoviEx Uranium unveils low-risk, high-reward Muntanga feasibility study
    Jan 24 2025
    GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical risks. The company plans to produce 2.20 million pounds of uranium annually over a 12-year lifespan. Major emphasised the potential for resource expansion from nearby satellite deposits, which could further enhance the project’s value. Additionally, he outlined the global uranium market dynamics, noting a deficit in supply and growing demand driven by new reactors, life extensions for existing reactors, and advancements in small modular reactors (SMRs). Looking ahead, GoviEx is targeting project construction by 2028 and is actively seeking debt financing and offtake agreements to move forward. Major said, "We’re already sharing our feasibility study with utilities to ensure we meet their requirements." Watch the full interview to learn more about GoviEx’s strategy for meeting global uranium demand. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates! #GoviExUranium #MutangaProject #UraniumMining #ZambiaResources #EnergyDemand #UraniumFeasibility #LowRiskMining #GlobalEnergy #NuclearEnergy #SmallModularReactors
    Show more Show less
    5 mins
  • ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough

    ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough
    Jan 24 2025
    ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer. Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by Professor Nicola Aceto at the Cancer Metastasis Laboratory in Zurich, where they discovered that FDA-approved cardiac drugs could break these clusters into individual cells. In mice and breast cancer patients, this approach showed potential to halt cancer progression. The CEO emphasised Parsortix's central role in identifying patients and monitoring treatment efficacy, predicting global interest and demand for the system. He also discussed ANGLE's broader work with cancer drug developers, including collaborations with companies like AstraZeneca and Eisai, to unlock new approaches to managing cancer. Newland concluded with optimism, envisioning a future where cancer could become a manageable condition, similar to how HIV/AIDS is now controlled. Discover more about this transformative research and ANGLE PLC’s contributions. Like this video, subscribe to Proactive’s channel, and enable notifications for future updates!" #ANGLEPLC #Parsortix #CancerResearch #CancerBreakthrough #Oncology #Metastasis #CirculatingTumorCells #MedicalInnovation #NatureMedicine #CancerAwareness
    Show more Show less
    11 mins
  • Iofina CEO on record iodine production in 2024, growth plans

    Iofina CEO on record iodine production in 2024, growth plans
    Jan 24 2025
    Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output. The company is also making strides with IO#11, set to begin production in Q3 2025, and ongoing discussions for IO#12, signalling further expansion. Becker emphasised strong global iodine demand, with prices climbing above $70 per kilogram, benefiting Iofina's operations. Despite minor shipping delays pushing sales into 2025, Becker assured investors of continued growth and progress. He also celebrated the company's safety track record, with no lost-time accidents since 2021. Stay tuned for more updates on Iofina PLC and its plans for the future. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!" #Iofina #IodineProduction #ChemicalIndustry #BusinessGrowth #RecordProduction #IO10Plant #IO11Plant #GlobalDemand #ChemicalSafety #ProactiveInvestors
    Show more Show less
    6 mins
  • Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results

    Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results
    Jan 24 2025
    Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials. The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide group out of 63 patients—a stark contrast to zero in the standard care group. This is particularly significant when compared to other trials, such as NAPOLI-3, which had only one complete response in nearly 400 patients. Mazzo also discussed Cohort B, which investigates a double-dose regimen of Certepetide to explore pharmacodynamic improvements and optimize treatment efficacy. In addition, Lisata released preliminary data from its iLSTA trial, which examines combining Certepetide with immunotherapy (Durvalumab) and cytotoxics for pancreatic cancer. Mazzo emphasized increased T-cell tumor penetration and higher partial response rates in early data, suggesting potential for enhanced treatment outcomes. Catch the full interview to learn more about these breakthroughs. Visit Proactive’s YouTube channel for updates, like this video, subscribe, and enable notifications to stay informed. #LisataTherapeutics #PancreaticCancer #ClinicalTrials #ASCENDTrial #Certepetide #CancerResearch #Immunotherapy #PharmaNews #BiotechInnovations #ProactiveInvestors
    Show more Show less
    7 mins